Coherus BioSciences (CHRS) Misses Q2 EPS by 60c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.50 +1.35%
Revenue Growth %: +40.6%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +40.6%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.71), $0.60 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $844 thousand, versus $10.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs
- Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
